-+ 0.00%
-+ 0.00%
-+ 0.00%

EU Medicines Agency Panel Recommends New Indication for J&J's Blood Cancer Drug

MT Newswires·10/16/2026 09:05:26
Listen to the news
09:05 AM EDT, 10/16/2026 (MT Newswires) -- The European Medicines Agency's human medicines committee issued a positive opinion recommending a change to the terms of the marketing approval for Talvey, developed by Johnson & Johnson's (JNJ.F) Janssen-Cilag International. The recommendation covers the use of Talvey, in combination with daratumumab and pomalidomide or in combination with daratumumab, to treat adults with relapsed or refractory multiple myeloma who previously received at least one prior therapy, according to a Friday notice. The drug is indicated as monotherapy to treat adults with the condition who have received at least three therapies.